Evaluation of backbone-cyclized HER2-binding 2-helix Affibody molecule for In Vivo molecular imaging

Nuclear Medicine and Biology

Volumn 40, Issue 3, 2013, Pages 378-386

  Honarvar, Hadis ^a   Jokilaakso, Nima ^b   Andersson, Karl ^a,c   Malmberg, Jennie ^d   Rosik, Daniel ^b   Orlova, Anna ^d   Karlström, Amelie Eriksson ^b   Tolmachev, Vladimir ^a   Järver, Peter ^b  

^a UPPSALA UNIVERSITY   (Sweden)

^b ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

^c Ridgeview Instruments AB   (Sweden)

^d UPPSALA UNIVERSITY   (Sweden)

Author keywords

2 helix protein; Affibody; HER2; Native chemical ligation, biodistribution; SPPS

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GALLIUM 68; GALLIUM PEP 09239 GA 68; GALLIUM TETRAXETAN ZHER2:342MIN GA 68; INDIUM 111; INDIUM PEP 09239 IN 111; INDIUM TETRAXETAN ZHER2:342MIN IN 111; PEP 09239; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; TRACER; UNCLASSIFIED DRUG;

ALPHA HELIX; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CYCLIZATION; DISSOCIATION CONSTANT; DISULFIDE BOND; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG IDENTIFICATION; DRUG PROTEIN BINDING; DRUG PURIFICATION; DRUG SYNTHESIS; DRUG TISSUE LEVEL; DRUG TUMOR LEVEL; DRUG UPTAKE; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; ISOTOPE LABELING; MOLECULAR IMAGING; MOLECULARLY TARGETED THERAPY; MOUSE; NATIVE CHEMICAL LIGATION; NONHUMAN; RADIOACTIVITY; SURFACE PLASMON RESONANCE; THERMOSTABILITY;

ANIMALS; CELL LINE, TUMOR; CYCLIZATION; GALLIUM RADIOISOTOPES; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; INDIUM RADIOISOTOPES; MICE; MOLECULAR IMAGING; PROTEIN STABILITY; PROTEIN STRUCTURE, SECONDARY; RECEPTOR, ERBB-2; RECOMBINANT FUSION PROTEINS; SUBSTRATE SPECIFICITY; TEMPERATURE;

EID: 84875265693     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2012.12.009     Document Type: Article

References (47)

1. Nygren P.Å. Alternative binding proteins: affibody binding proteins developed from a small three-helix bundle scaffold. FEBS J 2008, 275:2668-2676.
2. Löfblom J., Feldwisch J., Tolmachev V., Carlsson J., Ståhl S., Frejd F.Y. Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Lett 2010, 584:2670-2680.
3. Ahlgren S., Tolmachev V. Radionuclide molecular imaging using Affibody molecules. Curr Pharm Biotechnol 2010, 11:581-589.
4. Orlova A., Magnusson M., Eriksson T.L., Nilsson M., Larsson B., Hoiden-Guthenberg I., et al. Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res 2006, 66:4339-4348.
5. 111In-DOTA-Z EGFR:2377 Affibody molecule: aspect of the injected tracer amount. Eur J Nucl Med Mol Imaging 2010, 37:613-622.
6. Kronqvist N., Malm M., Gostring L., Gunneriusson E., Nilsson M., Hoiden Guthenberg I., et al. Combining phage and staphylococcal surface display for generation of ErbB3-specific Affibody molecules. Protein Eng Design Selection: PEDS 2011, 24:385-396.
7. Lindborg M., Cortez E., Hoiden-Guthenberg I., Gunneriusson E., von Hage E., Syud F., et al. Engineered high-affinity affibody molecules targeting platelet-derived growth factor receptor beta in vivo. J Mol Biol 2011, 407:298-315.
8. 111In-DOTA-ZIGF1R:4551. J Nucl Med 2012, 53:90-97.
9. 124I-labeled affibody molecule and trastuzumab in a murine xenograft model. J Nucl Med 2009, 50:417-425.
10. 125I-labeled anti-HER2 humanized monoclonal trastuzumab and ABY-025 affibody. Nucl Med Biol 2011, 38:1093-1102.
11. 68Ga-labeled affibody molecules. J Nucl Med 2010, 51:892-897.
12. 111In]ABY-025 metastatic detection capability in females with metastatic breast cancer. J Nucl Med 2012, 220. [Abstract].
13. Starovasnik M.A., Braisted A.C., Wells J.A. Structural mimicry of a native protein by a minimized binding domain. Proc Natl Acad Sci U S A 1997, 94:10080-10085.
14. Webster J.M., Zhang R., Gambhir S.S., Cheng Z., Syud F.A. Engineered two-helix small proteins for molecular recognition. Chembiochem 2009, 10:1293-1296.
15. Tolmachev V., Tran T.A., Rosik D., Sjöberg A., Abrahmsén L., Orlova A. Tumor targeting using affibody molecules: interplay of affinity, target expression level, and binding site composition. J Nucl Med 2012, 53:953-960.
16. 68Ga for PET imaging of HER2 expression. J Nucl Med 2009, 50:1492-1499.
17. Ren G., Webster J.M., Liu Z., Zhang R., Miao Z., Liu H., et al. In vivo targeting of HER2-positive tumor using 2-helix affibody molecules. Amino Acids 2012, 43:405-413.
18. 111In-labelled two-helix and three-helix Affibody molecules for in vivo molecular imaging. Eur J Nucl Med Mol Imaging 2012, 39:693-702.
19. Järver P., Mikaelsson C., Karlström A.E. Chemical synthesis and evaluation of a backbone-cyclized minimized 2-helix Z-domain. J Pept Sci 2011, 17:463-469.
20. Braisted A.C., Wells J.A. Minimizing a binding domain from protein A. Proc Natl Acad Sci U S A 1996, 93:5688-5692.
21. 99mTc-maEEE-Z(HER2:342), an Affibody molecule-based tracer for the detection of HER2 expression in malignant tumors. Bioconjug Chem 2007, 18:1956-1964.
22. 111In-labelled analogue. Eur J Nucl Med Mol Imaging 2010, 37:1356-1367.
23. Björke H., Andersson K. Automated, high-resolution cellular retention and uptake studies in vitro. Appl Radiat Isot 2006, 64:901-905.
24. Weissleder R. Molecular imaging in cancer. Science 2006, 312:1168-1171.
25. Nygren P.Å., Skerra A. Binding proteins from alternative scaffolds. J Immunol Methods 2004, 290:3-28.
26. 99mTc-labeled anti-HER2 Affibody molecules. Bioconjug Chem 2008, 19:2568-2576.
27. 3](+), and shows improved biodistribution with reduced hepatic radioactivity accumulation. Bioconjug Chem 2010, 21:2013-2022.
28. 99mTc-chelator engineering to improve tumour targeting properties of a HER2-specific Affibody molecule. Eur J Nucl Med Mol Imaging 2007, 34:1843-1853.
29. 186Re-maSGS-Z (HER2:342), a potential Affibody conjugate for systemic therapy of HER2-expressing tumours. Eur J Nucl Med Mol Imaging 2010, 37:260-269.
30. HER2:2395(-Cys) affibody molecule for targeting of HER2-expressing tumors. Mol Imaging Biol 2010, 12:54-62.
31. Orlova A., Nilsson F.Y., Wikman M., Widström C., Ståhl S., Carlsson J., et al. Comparative in vivo evaluation of technetium and iodine labels on an anti-HER2 affibody for single-photon imaging of HER2 expression in tumors. J Nucl Med 2006, 47:512-519.
32. Özcan F., Klein P., Lemmon M.A., Lax I., Schlessinger J. On the nature of low- and high-affinity EGF receptors on living cells. Proc Natl Acad Sci U S A 2006, 103:5735-5740.
33. Barta P., Malmberg J., Melicharova L., Strandgård J., Orlova A., Tolmachev V., et al. Protein interactions with HER-family receptors can have different characteristics depending on the hosting cell line. Int J Oncol 2012, 40:1677-1682.
34. Tao R.H., Maruyama I.N. All EGF(ErbB) receptors have preformed homo- and heterodimeric structures in living cells. J Cell Sci 2008, 121:3207-3217.
35. Björkelund H., Gedda L., Andersson K. Comparing the epidermal growth factor interaction with four different cell lines: intriguing effects imply strong dependency of cellular context. PLoS One 2011, 6:e16536.
36. Heppeler A., Froidevaux S., Mäcke H., Jermann E., Behe M., Powell P., et al. Radiometal-labelled macrocyclic chelator-derivatisedsomatostatin analogue with superb tumor-targeting properties and potential for receptor-mediated internal radiotherapy. Chem Eur J 1999, 5:1974-1981.
37. Tolmachev V. Imaging of HER-2 overexpression in tumors for guidingtherapy. Curr Pharm Des 2008, 14:2999-3019.
38. Froidevaux S., Eberle A.N., Christe M., Sumanovski L., Heppeler A., Schmitt J.S., et al. Neuroendocrine tumor targeting: study of novel gallium-labeled somatostatin radiopeptides in a rat pancreatic tumor model. Int J Cancer 2002, 98:930-937.
39. Antunes P., Ginj M., Zhang H., Waser B., Baum R.P., Reubi J.C., et al. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?. Eur J Nucl Med Mol Imaging 2007, 34:982-993.
40. Ahlgren S., Orlova A., Rosik D., Sandström M., Sjöberg A., Baastrup B., et al. Evaluation of Maleimide Derivative of DOTA for Site-Specific Labeling of Recombinant Affibody Molecules. Bioconjug Chem 2008, 19:235-243.
41. Tolmachev V., Mume E., Sjöberg S., Frejd F.Y., Orlova A. Influence of valency and labelling chemistry on in vivo targeting using radioiodinated HER2-binding Eur J Nucl Med. Mol Imaging 2009, 36:692-701.
42. Tolmachev V., Altai M., Sandström M., Perols A., Ericsson Karlström A., Boschetti F., et al. Evaluation of a maleimido derivative of NOTA for site-specific labeling of affibody molecules. Bioconjug Chem 2011, 22:894-902.
43. Altai M., Perols A., Eriksson Karlström A., Sandström M., Boschetti F., Orlova A., et al. Preclinical evaluation of anti-HER2 Affibody molecules site-specifically labeled with 111In using a maleimido derivative of NODAGA. Nucl Med Biol 2012, 39:518-529.
44. Malmberg J., Perols A., Varasteh Z., Altai M., Sandström M., Garske U., et al. Comparative evaluation of synthetic anti-HER2 Affibody molecules site-specifically labelled with (111)In using N-terminal DOTA, NOTA and NODAGA chelators in mice bearing prostate cancer xenografts. Eur J Nucl Med Molecul Imaging 2012, 39:481-492.
45. Hopp T.P., Woods K.R. Prediction of protein antigenic determinants from amino acid sequences. Proc Natl Acad Sci U S A 1981, 78:3824-3828.
46. Kyte J., Doolittle R.F. A simple method for displaying the hydropathic character of a protein. J Mol Biol 1982, 157:105-132.
47. Hosseinimehr S.J., Tolmachev V., Orlova A. Liver uptake of radiolabeled targeting proteins and peptides: considerations for targeting peptide conjugate design. Drug Discov Today 2012, 17:1224-1232.